Advocacy groups are urging regulatory authorities to launch an anticompetition investigation into major pharmaceutical companies’ strategic shifts following Brexit, according to a recent report by Fierce Pharma. As the UK’s departure from the European Union continues to reshape the pharmaceutical landscape, critics warn that some Big Pharma players may be leveraging the transition to entrench market dominance and hinder competition. The calls for scrutiny come amid growing concerns over drug pricing and access, highlighting the complex repercussions of Brexit on the industry’s competitive dynamics.
Big Pharma’s Brexit Shift Sparks Renewed Antitrust Concerns from Advocacy Groups
Recent shifts within the pharmaceutical industry, prompted by the United Kingdom’s departure from the European Union, have ignited fresh scrutiny from consumer advocacy groups and regulatory bodies alike. Critics argue that Big Pharma’s strategic realignment post-Brexit is creating barriers to competition,…
—-
Author : Victoria Jones
Publish date : 2025-10-05 14:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
